Prolight Diagnostics AB (LTS:0G5I) ROCE % : 5.97% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Prolight Diagnostics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prolight Diagnostics AB's annualized ROCE % for the quarter that ended in Dec. 2024 was 5.97%.

Prolight Diagnostics AB ROCE % Historical Data

The historical data trend for Prolight Diagnostics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prolight Diagnostics AB ROCE % Chart

Prolight Diagnostics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-3.28

-4.58

-57.63

-13.01

Prolight Diagnostics AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-173.39	-17.46	-31.64	-25.69	5.97

Prolight Diagnostics AB ROCE % Calculation

Prolight Diagnostics AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-26.681	/	( ( (282.533 - 18.449)	+	(166.331 - 20.255) )	/ 2 )
	=	-26.681	/	( (264.084	+	146.076)	/ 2 )
	=	-26.681	/	205.08
	=	-13.01 %

Prolight Diagnostics AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	8.3	/	( ( (151.347 - 19.529)	+	(166.331 - 20.255) )	/ 2 )
	=	8.3	/	( ( 131.818	+	146.076 )	/ 2 )
	=	8.3	/	138.947
	=	5.97 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Prolight Diagnostics AB (LTS:0G5I) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Prolight Diagnostics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Prolight Diagnostics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prolight Diagnostics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Prolight Diagnostics AB (LTS:0G5I) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PRLD:Sweden

Address

Gasverksgatan 3A, Lund, SWE, 222 29

Website

https://www.prolightdx.com

Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.

Prolight Diagnostics AB Headlines

No Headlines